Menu Search
Equities

Airway Medix SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
D1C:FRA

Airway Medix SA

Actions
  • Price (EUR)0.062
  • Today's Change-0.001 / -1.12%
  • Shares traded2.00k
  • 1 Year change+20.62%
  • Beta0.4577
Data delayed at least 15 minutes, as of Feb 16 2026 08:37 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Airway Medix SA is a Poland-based company engaged in the biotechnology and medical research industry. The Company focuses on the research, development and commercialization of devices for single use in mechanically ventilated patients in intensive care units (ICU), and patients with life-threatening and anesthesiology division. It offers closed suction system, a closed cleaning system for simple hygiene treatment, endotracheal intubation tubes and oral care solution for cleaning the mouth.

  • Revenue in PLN (TTM)4.00k
  • Net income in PLN835.00k
  • Incorporated2013
  • Employees1.00
  • Location
    Airway Medix SAul. Gen. Jozefa Zajaczka 11/14WARSZAWA 01-510PolandPOL
  • Phone+48 222434799
  • Fax+48 223009987
  • Websitehttps://airway-medix.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.